References
Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery
rate: A practical and powerful approach to multiple testing.Journal of the Royal Statistical Society B, 57 , 289-300
Baandrup Kristiansen, M. N. , Veidal, S. S., Christoffersen, C., Feigh,
M., Vrang, N., Roth, J. D., …, Jelsing, J. (2019) Validity of
biopsy-based drug effects in a diet-induced obese mouse model of
biopsy-confirmed NASH. BMC Gastroenterology, 19 , 228
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K.,
Rinella, M., …, Sanyal, A.J. (2018) The diagnosis and management
of nonalcoholic fatty liver disease: Practice guidance from the American
Association for the Study of Liver Diseases. Hepatology,67, 328-357
Clapper, J. R., Hendricks, M. D., Gu, G., Wittmer, C., Dolman, C. S.,
Herich, J., …, Roth, J. D. (2013) Diet-induced mouse model of
fatty liver disease and nonalcoholic steatohepatitis reflecting clinical
disease progression and methods of assessment. American Journal of
Physiology - Gastrointestinal and Liver Physiology , 305 ,
G483-95
Costa-Silva, J., Domingues, D., & Lopes, F.M. (2017) RNA-Seq
differential expression analysis: An extended review and a software
tool. PLoS One , 12 , e0190152.
Diehl, A.M., & Day, C. (2017) Cause, Pathogenesis, and treatment of
nonalcoholic steatohepatitis. New England Journal of Medicine,377 , 2063-2072
Dulai, P.S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi,
Z., …, Loomba, R. (2017) Increased risk of mortality by fibrosis
stage in nonalcoholic fatty liver disease: Systematic review and
meta-analysis. Hepatology, 65 , 1557-1565
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stal, P.,
Kechagias, S., & Hultcrantz, R. (2015) Fibrosis stage is the strongest
predictor for disease-specific mortality in NAFLD after up to 33 years
of follow-up. Hepatology, 61 , 1547–1554
Erion, M. D., Cable, E. E., Ito, B. R., Jiang, H., Fujitaki, J. M.,
Finn, P. D., …, Linemeyer, D. L. (2007) Targeting thyroid hormone
receptor‐beta agonists to the liver reduces cholesterol and
triglycerides and improves the therapeutic index. Proceedings of
the National Academy of Sciences of the United States of America,104 :15490‐15495
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani,
S., Caballeria, J.,…,Razavi, H. (2018) Modeling NAFLD disease
burden in China, France, Germany, Italy, Japan, Spain, United Kingdom,
and United States for the period 2016-2030. Journal of
Hepatology, 69 , 896-904
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A.J. (2018)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates
an exponential increase in burden of disease. Hepatology,67 , 123-133
Garber, K. (2019) The new liver epidemic. Nature Biotechnology,37 , 209-214
Carrasco-Torres, G., Fattel-Fazenda, S., López-Alvarez, G. S.,
García-Román, R., Villa-Treviño, S., Vásquez-Garzón, V. R. (2016) The
transmembrane transporter ABCC3 participates in liver cancer progression
and is a potential biomarker. Tumour Biology, 37 ,
2007-2014
Hansen, H. H., Feigh, M., Veidal S. S., Rigbolt, K. T., Vrang, N., &
Fosgerau, K. Mouse models of nonalcoholic steatohepatitis in preclinical
drug development. Drug Discovery Today , 22 , 1707-1718
Harrison, S.A., Bashir, M.R., Guy, C.D., Zhou, R., Moylan, C.A., Frias,
J.P., …, Moussa, S. E. (2019) Resmetirom (MGL-3196) for the
treatment of non-alcoholic steatohepatitis: a multicentre, randomised,
double-blind, placebo-controlled, phase 2 trial. The Lancet,394 , 2012-2024.
Kelly, M. J., Pietranico‐Cole, S., Larigan, J. D., Haynes, N. E.,
Reynolds, C. H., Scott, N., …, Tilley J. (2014) Discovery of
2‐[3,5‐dichloro‐4‐(5‐
isopropyl‐6‐oxo‐1,6‐dihydropyridazin‐3‐yloxy)phenyl]‐3,5‐dio
xo‐2,3,4,5‐ tetrahydro[1,2,4]triazine‐6‐carbonitrile (MGL‐3196), a
Highly Selective Thyroid Hormone Receptor beta agonist in clinical
trials for the treatment of dyslipidemia. Journal of Medicinal
Chemistry 57 , 3912‐3923.
Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J.,
Cummings, O.W., …, Sanyal, A. J. (2005) Design and validation of
a histological scoring system for nonalcoholic fatty liver disease.Hepatology, 41 , 1313-1321
Krämer, A., Green, J., Pollard, J. Jr, & Tugendreich, S. (2014) Causal
analysis approaches in Ingenuity Pathway Analysis.Bioinformatics, 30 , 523-530.
Krause, C., Grohs, M., El Gammal, A. T., Wolter, S., Lehnert, H., Mann,
O., Mittag, J., & Kirchner, H. (2018) Reduced expression of thyroid
hormone receptor β in human nonalcoholic steatohepatitis.Endocrine Connections 7 , 1448-1456
Kristiansen, M. N., Veidal, S. S., Rigbolt, K. T., Tølbøl, K. S., Roth,
J. D., Jelsing, J., Vrang, N., & Feigh, M. (2016) Obese diet-induced
mouse models of nonalcoholic steatohepatitis-tracking disease by liver
biopsy. World Journal of Hepatology , 8 , 673-84
Martagon, A. J., Lin, J. Z., Cimini, S. L., Webb, P., & Phillips, K. J.
(2015) The amelioration of hepatic steatosis by thyroid hormone receptor
agonists is insufficient to restore insulin sensitivity in ob/ob mice.PLoS One 10 , e0122987
Nien, H. C., Sheu, J. C., Chi, Y. C., Chen, C. L., Kao, J. H., & Yang,
W. S. (2018) One-year weight management lowers
lipopolysaccharide-binding protein and its implication in
metainflammation and liver fibrosis. PLoS One 13 ,
e0207882
Perra, A., Simbula, G., Simbula, M., Pibiri, M., Kowalik, M. A., Sulas,
P., …, Columbano, A. (2008) Thyroid hormone (T3) and TRβ agonist
GC-1 inhibit/reverse nonalcoholic fatty liver in rats. The FASEB
Journal 22 , 2981-2989
Sinha, R. A., Bruistroop, E., Singh, B. K., & Yen, P. M. (2019)
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of
Thyroid Hormones, Metabolites, and Agonists. Thyroid,29 , 1173-1191
Thompson, K. J., Austin, R. G., Nazari, S. S., Gersin, K. S., Iannitti,
D. A., McKillop, I. H. (2018) Altered fatty acid-binding protein 4
(FABP4) expression and function in human and animal models of
hepatocellular carcinoma. Liver International 38 ,
1074-1083
Vatner, D. F., Weismann, D., Beddow, S. A., Kumashiro, N., Erion, D. M.,
Liao, X. H., …, Samuel, V. T. (2013) Thyroid hormone receptor-β
agonists prevent hepatic steatosis in fat-fed rats but impair insulin
sensitivity via discrete pathways. American Journal of Physiology
- Endocrinology and Metabolism 305 , E89-100
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., &
Wymer, M. (2016) Global epidemiology of nonalcoholic fatty liver
disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology, 64 , 73–84